bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

BLUE has been the topic of several other reports. Robert W. Baird cut their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Wells Fargo & Company decreased their target price on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 25th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $3.00 to $0.50 in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.03.

bluebird bio Stock Up 2.1 %

Shares of NASDAQ:BLUE opened at $0.38 on Tuesday. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The stock has a fifty day simple moving average of $0.45 and a two-hundred day simple moving average of $0.75. bluebird bio has a 12-month low of $0.29 and a 12-month high of $5.53. The stock has a market capitalization of $73.46 million, a price-to-earnings ratio of -0.20 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $18.57 million during the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. On average, research analysts anticipate that bluebird bio will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

Several hedge funds have recently bought and sold shares of BLUE. Allegheny Financial Group LTD bought a new position in shares of bluebird bio in the second quarter worth about $25,000. Verition Fund Management LLC bought a new stake in bluebird bio during the 3rd quarter worth approximately $42,000. Bayesian Capital Management LP purchased a new position in bluebird bio during the first quarter valued at approximately $52,000. SG Americas Securities LLC boosted its position in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.